AVXL
Anavex Life Sciences Corp. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website anavex.com
- Employees(FY) 40
- ISIN US0327973006
Performance
-10.09%
1W
-9.31%
1M
+62.72%
3M
+116.54%
6M
-9.99%
YTD
+5.94%
1Y
Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Technical Analysis of AVXL 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 07:30
- 2024-12-08 18:30
- 2024-12-02 07:30
- 2024-12-01 18:30
- 2024-11-26 09:29
- 2024-11-26 07:30
- 2024-11-25 18:30
- 2024-11-25 07:30
- 2024-11-24 18:30
- 2024-10-31 04:00
- 2024-10-30 16:00
- 2024-10-17 07:30
- 2024-10-16 19:30
- 2024-10-09 05:01
- 2024-09-20 08:34
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?(Simply Wall St.)
- 2024-09-03 07:30
- 2024-09-02 19:30
- 2024-08-06 07:48
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot(Associated Press Finance)
- 2024-08-06 07:30
- 2024-08-05 19:30
- 2024-08-01 07:30
- 2024-07-31 19:30
- 2024-07-30 07:30
- 2024-07-30 05:15
Anavex Life Sciences Files $150 Million Shelf(MT Newswires)
- 2024-07-29 19:30
- 2024-07-29 08:39
- 2024-07-29 06:22
Anavex seek EMA approval despite shaky pivotal Alzheimer’s trial data(Clinical Trials Arena)
- 2024-07-28 17:00
- 2024-07-28 05:00
- 2024-07-09 10:37
Page 1 of 7
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.